Affymax and Takeda Report Additional Phase 3 Clinical Trial (AFFY)

Affymax AFFY and Takeda Pharmaceutical Company Limited , today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia. Building on the primary analysis of the EMERALD studies, which showed that once-monthly peginesatide was comparable to epoetin given up to 13 times a month in maintaining hemoglobin levels with a generally similar adverse event rate, these data provide additional information on the maintenance of Hb within treatment targets over time, as well as cardiovascular safety results of this once-monthly agent in the dialysis patients studied.1,2 These data, along with a demographic analysis from the dialysis studies, were part of three poster presentations at the National Kidney Foundation's Spring Clinical Meetings in Las Vegas, Nevada.